[codicts-css-switcher id=”346″]

Global Law Experts Logo
ccs merger procedure guidelines singapore

Our Expert in Singapore

Singapore M&A 2026, CCS Merger Procedure Guidelines & Form M1: Practical Deal‑team Checklist

By Global Law Experts
– posted 1 hour ago

The revised CCS merger procedure guidelines Singapore deal teams have been anticipating took effect on 1 May 2026, reshaping how merger notifications are prepared, filed and reviewed under the Competition Act 2004. Alongside the updated guidelines, CCS released an overhauled Form M1 that expands the information parties must submit at the notification stage, while simultaneously introducing a tighter Phase‑1 review window and formalised extension mechanics. For in‑house counsel, private equity sponsors and transaction lawyers coordinating cross‑border ASEAN deals, these changes demand immediate recalibration of closing timetables, evidence‑gathering workflows and multi‑jurisdiction filing sequences.

This article provides a comprehensive, practice‑ready walkthrough of every material change, complete with comparison tables, a document‑mapping checklist for the new Form M1, and a step‑by‑step deal‑team action plan for the post‑1 May 2026 merger control landscape in Singapore.

Executive Summary & TL;DR for Deal Teams

If you are advising on or managing a Singapore‑nexus transaction, the three facts that matter most right now are:

  • Effective date. The revised CCS Merger Procedure Guidelines and the updated Form M1 apply to all notifications filed on or after 1 May 2026. Notifications submitted before that date continue under the previous regime.
  • Phase‑1 timeline change. The standard Phase‑1 preliminary assessment period has been shortened from the previous indicative 30 working days to 25 working days. However, CCS now has an express power to extend Phase‑1 by up to an additional 20 working days (for a potential total of 45 working days) where specified grounds are met, a significant new variable for deal timetabling.
  • Immediate action items. Deal teams should (a) update all template M&A clearance timelines to reflect the new baseline and extension scenarios, (b) begin collecting expanded Form M1 data sets during due diligence rather than post‑signing, and (c) engage CCS in a Pre‑Notification Discussion (PND) for any transaction likely to attract scrutiny.

What Changed, A Short Legal Summary

On 27 March 2026, the Competition and Consumer Commission of Singapore (CCS) announced the finalisation of revisions to its Guidelines on Merger Procedures. The previous version of the CCS Guidelines had been in effect since 1 February 2022. The revised Merger Procedure Guidelines and consequential amendments to other CCS guidelines came into effect on 1 May 2026.

CCS stated that the amendments are intended to provide businesses with greater clarity on its procedures, while incorporating stakeholder feedback received during the public consultation launched in late 2025. The key changes fall into four categories:

  • Accelerated Phase‑1 baseline. The indicative timeline for the Phase‑1 preliminary assessment has been compressed, giving deal teams earlier signals on whether a transaction raises competition concerns.
  • Formalised extension mechanics. The revised guidelines now expressly provide that CCS may extend the Phase‑1 review period by up to an additional 20 working days under specified circumstances, codifying what was previously an informal practice.
  • Expanded Form M1. The updated notification form requires more granular economic and market data at the point of filing, including detailed corporate structure charts and expanded documentation schedules.
  • Publication upon acceptance. Upon acceptance of a satisfactory application that meets the requirements in Form M1, CCS will publish the details of the merger situation on its public register, formalising a transparency commitment.

These changes apply under the Competition Act 2004 and were gazetted in the Singapore Electronic Gazette on 27 March 2026.

CCS Merger Procedure Guidelines Singapore, Timelines: Phase‑1, Extensions & Phase‑2 Explained

The most consequential changes in the revised CCS merger procedure guidelines Singapore practitioners must navigate involve the mechanics and duration of each review phase. Below is a side‑by‑side comparison of the key timeline elements before and after 1 May 2026.

Element Pre‑1 May 2026 Post‑1 May 2026
Phase‑1 standard timeline 30 working days (indicative) 25 working days from acceptance of a complete Form M1
Phase‑1 extension Informal; CCS could request additional time on a case‑by‑case basis without a codified cap CCS may extend by up to 20 additional working days (total potential Phase‑1 period: 45 working days); grounds and process expressly set out in the revised Guidelines
Phase‑2 investigation 120 working days (indicative) following Phase‑1 referral 120 working days (unchanged); the clock remains indicative and may be extended in complex cases
Form M1 content Previous Form M1 fields (summary financial and market data) Expanded Form M1 requiring detailed economic evidence, corporate structure charts, internal documents and updated declarations
Publication on public register At CCS’s discretion CCS will publish details upon acceptance of a satisfactory Form M1 application

Phase‑1: Acceptance to Decision Under the Revised CCS Merger Procedure Guidelines

Once CCS receives a complete Form M1 that meets all filing requirements, the Phase‑1 review clock starts. Under the previous indicative timetable, deal teams could expect a preliminary assessment to be completed within 30 working days. The revised guidelines shorten this baseline to 25 working days, a meaningful acceleration for time‑sensitive transactions. At the conclusion of Phase‑1, CCS will either clear the merger, clear it subject to commitments, or refer it to a Phase‑2 investigation.

The practical implication is that deal teams now receive an earlier directional signal. Industry observers expect that for straightforward, non‑problematic mergers, the shortened window will translate into faster clearance and a tighter path from signing to closing.

Phase‑1 Extensions, Grounds, Timing and Practical Responses

Can CCS extend Phase‑1, and under what grounds? Yes. The revised guidelines now expressly provide that CCS may extend the Phase‑1 review period by up to an additional 20 working days where it determines that the merger raises issues requiring further analysis, where additional information is needed from the parties or third parties, or where the complexity of the transaction warrants additional review time.

For deal teams, this means the effective Phase‑1 window ranges from 25 to 45 working days. The likely practical effect will be that transactions in concentrated markets, or those involving novel theories of harm (for example, digital platforms, nascent competition, or conglomerate effects), will face extensions more frequently. To mitigate extension risk, deal teams should front‑load economic evidence in the Form M1 submission and address foreseeable competition concerns proactively in cover submissions.

Phase‑2: Investigation Timing and Practical Holds

If CCS refers a merger to Phase‑2, the indicative 120‑working‑day investigation period remains unchanged. During Phase‑2, CCS conducts a detailed competitive assessment, solicits third‑party views, and may engage with the merging parties on possible remedies or commitments. Parties should be prepared for the total M&A clearance timeline, from Form M1 submission through Phase‑2 decision, to extend to approximately seven to eight calendar months in complex cases, factoring in public holidays and any information requests that stop the clock.

Form M1, New CCS Form M1 Requirements and How to Prepare It

The updated Form M1 is the most operationally demanding change in the revised CCS merger procedure guidelines Singapore deal teams must address. What new information does the updated Form M1 require, and how should deal teams prepare it? The answer is that CCS has expanded the notification form to capture a richer dataset at the point of filing, reducing the need for follow‑up information requests during Phase‑1 and enabling a faster initial assessment.

The following table maps the key Form M1 fields to the supporting documents and data sets that deal teams should assemble.

Form M1 Field Documents / Data to Attach
Parties to the merger Full corporate structure charts (ultimate beneficial owners through to relevant subsidiaries); registration documents
Description of the merger situation Transaction agreements (SPA, shareholders’ agreement, JV terms); board resolutions authorising the deal
Overlapping products and services Product‑by‑product revenue and volume data for Singapore and ASEAN; market share estimates with methodology notes
Market definition and competitive landscape Commissioned market studies or internal strategy documents defining addressable markets; competitor lists with estimated shares
Vertical and conglomerate relationships Supply‑chain maps; customer and supplier lists with switching‑cost data
Efficiencies and counterfactual Board papers or management presentations projecting synergies; counterfactual scenario analysis
Internal documents Board minutes, investment committee papers, strategy presentations prepared for senior management that discuss the rationale for and competitive implications of the deal
Contact details for customers, competitors and suppliers Names, addresses and contact persons for the top 10 customers, competitors and suppliers in each overlap market
Declarations Signed declarations by authorised officers confirming completeness and accuracy of the submission

Common Pitfalls When Completing Form M1

Even experienced deal teams encounter recurring issues that delay acceptance of the Form M1 and, consequently, the start of the Phase‑1 clock. The most common pitfalls include:

  • Incomplete corporate structure charts. CCS expects a full chain from the ultimate beneficial owner down to every entity that participates in the overlap markets. Missing intermediate holding companies or offshore SPVs trigger information requests.
  • Insufficient market share evidence. Relying solely on publicly available reports without providing the underlying methodology and data sources often fails to satisfy CCS’s requirements.
  • Late identification of vertical relationships. Parties frequently underestimate the scope of vertical and conglomerate linkages. Map the entire supply chain early in the due diligence process.
  • Missing internal documents. The updated Form M1 places greater emphasis on internal strategy documents. Board minutes and investment committee papers should be reviewed, logged and redacted (where necessary for privilege) well before filing.
  • Unsigned or incomplete declarations. Ensure that every declaration is signed by an officer with actual authority, and that the scope of the declaration matches the content of the submission.

Sample Form M1 Submission Checklist

Deal teams should use the following CCS notification checklist as a pre‑flight document before submitting Form M1:

  1. Corporate structure charts (ultimate beneficial owner to relevant subsidiaries)
  2. Executed transaction documents (SPA, JV agreement, side letters)
  3. Board resolutions and authorisations
  4. Product‑by‑product revenue/volume data (Singapore and ASEAN, three‑year historical)
  5. Market share estimates with source methodology
  6. Competitor, customer and supplier contact lists (top 10 per overlap market)
  7. Internal strategy documents (board papers, investment committee memos)
  8. Supply‑chain and vertical relationship maps
  9. Efficiency and synergy analysis with supporting evidence
  10. Counterfactual scenario analysis
  11. Market study or commissioned economic report (if available)
  12. Draft confidentiality ring proposal (for sensitive data)
  13. Signed declarations by authorised officers
  14. Privilege log for any documents withheld
  15. Cover submission addressing foreseeable competition concerns

Pre‑Notification Options: PNDs and Voluntary Engagement

Is a pre‑notification discussion (PND) advisable? In most cases involving transactions that raise or may raise competition concerns, the answer is yes. Merger parties intending to make an application may approach CCS for a confidential PND before submitting Form M1, allowing them to test the scope of the notification, identify likely areas of concern, and receive informal feedback on the evidence CCS is likely to require.

A PND is not binding on CCS, it does not pre‑determine the outcome of any substantive assessment, but it offers significant practical benefits. Deal teams can use PNDs to clarify market definition expectations, discuss the scope of internal documents CCS expects, and explore whether commitments or remedies might be needed to address competition concerns.

To request a PND, deal teams should prepare a short briefing paper summarising the transaction, the parties, the overlap markets and any preliminary competition analysis. CCS typically schedules PNDs within two to three weeks of a request, and the discussions are conducted on a confidential basis. Early indications suggest that deal teams who invest in a thorough PND process under the revised guidelines are less likely to face delays at the Form M1 acceptance stage.

Which Transactions Now Trigger Notification or Faster CCS Scrutiny

Which deals now trigger notification or faster CCS scrutiny after the 2026 changes? Singapore’s merger control regime remains voluntary, there is no mandatory notification threshold, but CCS retains the power to investigate any merger that has resulted, or may be expected to result, in a substantial lessening of competition. The revised CCS merger procedure guidelines Singapore filing teams reference do not alter the jurisdictional triggers, but the expanded Form M1 and faster Phase‑1 review increase the stakes of getting the notification decision wrong.

The following table identifies the deal types most likely to attract CCS attention.

Deal Type Likelihood of CCS Scrutiny Practical Action
Horizontal mergers with combined market share exceeding 40% in any relevant Singapore market High File proactively; prepare detailed market share evidence and efficiency arguments in Form M1
Vertical mergers creating foreclosure risks (e.g., exclusive supply arrangements, platform integration) Moderate to High Map the full supply chain; address foreclosure theories in the cover submission; consider PND
Acquisitions eliminating nascent or potential competitors (particularly in digital, fintech and healthcare sectors) Moderate, and rising Engage with CCS early via PND; provide internal documents evidencing the target’s competitive potential

Even where combined market shares fall below 40%, transactions that create or strengthen a dominant position, eliminate a significant competitive constraint, or raise concerns about coordinated effects should be evaluated for voluntary notification. Industry observers expect CCS to pay heightened attention to digital economy transactions and deals involving data‑rich targets in the post‑2026 environment.

Cross‑Border Filings, Sequencing CCS with ASEAN and Other Regulators

How should cross‑border M&A Singapore deal teams coordinate filings to avoid timing risk? For transactions with ASEAN‑wide footprints, sequencing merger notifications across multiple jurisdictions is critical to preventing one regulator’s timeline from blocking another’s closing schedule.

The revised CCS guidelines do not change Singapore’s voluntary notification regime, but the tighter Phase‑1 baseline and new extension mechanics have knock‑on effects for multi‑jurisdiction deal timetables. Key coordination principles include:

  • Parallel filing where possible. File with CCS and the Malaysian Aviation Commission (MAVCOM), MyCC (Malaysia Competition Commission), the Thailand Trade Competition Commission or Indonesia’s KPPU concurrently. Stagger only where confidentiality constraints or condition‑precedent structures require sequential filing.
  • Harmonise market definitions. Use a consistent market definition framework across jurisdictions to avoid conflicting evidence submissions. Where regulators use different geographic or product market approaches, prepare jurisdiction‑specific annexes but maintain a common factual base.
  • Align evidence schedules. The expanded Form M1 data requirements overlap significantly with the information required by other ASEAN regulators. Centralise data collection during due diligence to avoid duplication and ensure consistency.
  • Manage confidentiality across borders. Coordinate confidentiality ring proposals so that commercially sensitive data shared with CCS is subject to equivalent protections in parallel filings. Cross‑border data transfer requirements (particularly under Singapore’s PDPA and equivalent legislation in other jurisdictions) must be addressed in each filing.
  • Build in buffer for extensions. When setting the long‑stop date in the transaction agreement, account for the possibility that CCS may invoke its new Phase‑1 extension power. A long‑stop date that accommodates 45 working days for CCS Phase‑1 plus the longest mandatory review period in any other filing jurisdiction provides adequate margin.

Evidence and Economic Appendix Coordination Across Jurisdictions

For transactions requiring economic expert evidence, a single commissioned economic report addressing competitive effects across the ASEAN region, with jurisdiction‑specific chapters, is more efficient than producing separate reports for each regulator. This approach ensures analytical consistency and reduces the risk that differing methodologies produce conflicting market share estimates or competitive effects conclusions.

Practical Deal‑Team Checklist and Sample Merger Timelines Singapore, Ready to Use

The following 15‑step checklist maps the critical actions for a Singapore merger notification under the revised CCS merger procedure guidelines Singapore deal teams must now follow. Timings are expressed relative to signing (S) and target closing (C).

  1. S−60 days: Competition risk assessment. During due diligence, evaluate whether the transaction raises horizontal, vertical or conglomerate competition concerns in Singapore. Commission market share analysis.
  2. S−45 days: Begin Form M1 data collection. Start assembling corporate structure charts, product‑level revenue data, internal strategy documents and customer/supplier lists.
  3. S−30 days: Request PND with CCS (if applicable). Prepare a two‑to‑three‑page briefing paper and request a confidential meeting.
  4. S−20 days: Conduct PND meeting. Obtain informal CCS feedback on market definition, evidence expectations and likely areas of concern.
  5. S−10 days: Finalise transaction documents. Ensure SPA condition‑precedent language accommodates the new CCS timeline scenarios (25 working days baseline, up to 45 with extension, 120 for Phase‑2).
  6. S day: Sign the transaction. Lock in the deal terms.
  7. S+5 days: Complete Form M1 preparation. Assemble all supporting documents per the Form M1 submission checklist above.
  8. S+10 days: Submit Form M1 to CCS. File the completed notification with all supporting evidence, declarations and any proposed confidentiality ring.
  9. S+12 days: CCS acknowledgement and completeness check. CCS reviews the submission for completeness and may request clarifications.
  10. S+15 days: Form M1 accepted; Phase‑1 clock starts. CCS publishes merger details on the public register upon acceptance.
  11. S+40 days (25 working days after acceptance): Phase‑1 decision expected. If no extension, CCS issues clearance, clearance with commitments, or referral to Phase‑2.
  12. S+40 to S+60 days: Phase‑1 extension window (if invoked). CCS may extend Phase‑1 by up to 20 additional working days. Deal teams should respond promptly to any additional information requests.
  13. S+60 days: Latest Phase‑1 decision (if extended). Final Phase‑1 outcome; if cleared, proceed to closing mechanics.
  14. S+60 to C: Satisfy remaining conditions precedent. Complete any parallel regulatory filings, obtain board approvals, and prepare closing deliverables.
  15. C day: Close the transaction. Execute closing mechanics upon receipt of all necessary clearances.

Fast‑track scenario (30‑day accelerated deals): For transactions with no overlap or de minimis market shares, consider compressing steps 1–8 by beginning Form M1 preparation during the exclusivity/LOI phase rather than post‑signing. Where a thorough PND has been conducted and CCS has indicated no concerns, the Phase‑1 window may conclude well within 25 working days, enabling closing as early as S+35 to S+45 calendar days.

Conclusion and Next Steps

The revised CCS merger procedure guidelines Singapore transaction teams must now comply with represent the most significant overhaul of Singapore’s merger notification framework since the Guidelines were last updated in February 2022. The compressed Phase‑1 baseline, the formalised extension mechanics, and the expanded Form M1 requirements collectively demand that deal teams rethink their preparation workflows, closing timetables and cross‑border filing strategies. Practitioners who begin Form M1 data collection during due diligence, invest in pre‑notification engagement with CCS, and build sufficient timeline buffer for extension scenarios will be best positioned to navigate the new regime efficiently and minimise deal execution risk.

Need Legal Advice?

This article was produced by Global Law Experts. For specialist advice on this topic, contact Soo Chye LEE at Oaks Legal LLC, a member of the Global Law Experts network.

Sources

  1. Competition & Consumer Commission of Singapore, Revisions to CCS’s Merger Procedure Guidelines
  2. CCS, Merger Notification Procedures
  3. Singapore Electronic Gazette, Competition Act / Notices (2026)
  4. Rajah & Tann Asia, Revisions to CCS’s Merger Procedure Guidelines in Effect from 1 May 2026
  5. Jones Day, Singapore Updates Merger Control Regime
  6. Allen & Gledhill, Revised CCS Merger Procedure Guidelines in Effect 1 May 2026
  7. Drew & Napier, ICLG Merger Control 2026 Singapore Chapter
  8. Practical Law / Thomson Reuters, Revised CCS Merger Procedure Guidelines
  9. CCS Guidelines on Merger Procedures (Archival PDF)

FAQs

What are the Phase‑1 and Phase‑2 timelines under the revised CCS Merger Procedure Guidelines?
Phase‑1 is CCS’s preliminary assessment period, now set at a baseline of 25 working days from acceptance of a complete Form M1, with a possible extension of up to 20 additional working days. Phase‑2, for transactions referred for detailed investigation, remains at an indicative 120 working days.
The updated Form M1 requires expanded economic and market evidence, including product‑level revenue and volume data, detailed corporate structure charts, internal strategy documents, and specific document attachments mapped to each section of the form.
Singapore’s regime remains voluntary, but transactions with combined market shares exceeding 40%, vertical mergers creating foreclosure risks, and acquisitions eliminating nascent competitors are most likely to attract CCS scrutiny. The expanded Form M1 raises the evidential bar for all notifying parties.
Yes. The revised guidelines expressly allow CCS to extend Phase‑1 by up to 20 additional working days where the merger raises issues requiring further analysis, additional information is needed, or the transaction’s complexity warrants additional review time.
Yes. Upon acceptance of a satisfactory application meeting the requirements in Form M1, CCS will publish the details of the merger situation on its public register.
No. A PND is confidential guidance that does not bind CCS’s eventual substantive assessment, but it helps merger parties clarify evidence expectations and identify potential competition concerns before filing.
Teams should parallel‑file where feasible, harmonise market definitions across jurisdictions, centralise data collection during due diligence, and set long‑stop dates that accommodate the maximum possible CCS Phase‑1 period (45 working days) plus the longest review period in any other filing jurisdiction.

Find the right Legal Expert for your business

The premier guide to leading legal professionals throughout the world

Specialism
Country
Practice Area
LAWYERS RECOGNIZED
0
EVALUATIONS OF LAWYERS BY THEIR PEERS
0 m+
PRACTICE AREAS
0
COUNTRIES AROUND THE WORLD
0
Join
who are already getting the benefits
0

Sign up for the latest legal briefings and news within Global Law Experts’ community, as well as a whole host of features, editorial and conference updates direct to your email inbox.

Naturally you can unsubscribe at any time.

Newsletter Sign Up
About Us

Global Law Experts is dedicated to providing exceptional legal services to clients around the world. With a vast network of highly skilled and experienced lawyers, we are committed to delivering innovative and tailored solutions to meet the diverse needs of our clients in various jurisdictions.

Global Law Experts App

Now Available on the App & Google Play Stores.

Social Posts
[wp_social_ninja id="50714" platform="instagram"]
[codicts-social-feeds platform="instagram" url="https://www.instagram.com/globallawexperts/" template="carousel" results_limit="10" header="false" column_count="1"]

See More:

Contact Us

Stay Informed

Join Mailing List
About Us

Global Law Experts is dedicated to providing exceptional legal services to clients around the world. With a vast network of highly skilled and experienced lawyers, we are committed to delivering innovative and tailored solutions to meet the diverse needs of our clients in various jurisdictions.

Social Posts
[wp_social_ninja id="50714" platform="instagram"]
[codicts-social-feeds platform="instagram" url="https://www.instagram.com/globallawexperts/" template="carousel" results_limit="10" header="false" column_count="1"]

See More:

Global Law Experts App

Now Available on the App & Google Play Stores.

Contact Us

Stay Informed

Join Mailing List

GLE

Lawyer Profile Page - Lead Capture
GLE-Logo-White
Lawyer Profile Page - Lead Capture

Singapore M&A 2026, CCS Merger Procedure Guidelines & Form M1: Practical Deal‑team Checklist

Send welcome message

Custom Message